SCHEMBL475343

SCHEMBL475343

O=c1ccn([C@H]2C[C@H](O)[C@@H](C(F)OP(=O)(O)O)O2)c(=O)[nH]1

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DUT P33316 4/20 0.52
P2RY2 P41231 13/20 0.43
P2RY6 Q15077 7/20 0.43
P2RY4 P51582 6/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1129230 0.92 DUT (0.54) DUTP2RY2P2RY6P2RY4
SCHEMBL21647246 0.91 DUT (0.48) DUTP2RY2P2RY6P2RY4
SCHEMBL1129336 0.90 DUT (0.52) DUTP2RY2P2RY6P2RY4
SCHEMBL11686095 0.88 DUT (0.49) DUTP2RY2P2RY6P2RY4
SCHEMBL986334 0.87 DUT (0.52) DUTP2RY2P2RY6P2RY4
SCHEMBL9765650 0.87 DUT (0.55) DUTP2RY2P2RY6P2RY4
SCHEMBL7628981 0.86 DUT (0.45) DUTP2RY2P2RY6P2RY4
SCHEMBL4954183 0.83 DUT (0.53) DUTP2RY2P2RY6P2RY4
SCHEMBL51722 0.83 DUT (0.53) DUTP2RY2P2RY6P2RY4
SCHEMBL3392998 0.83 DUT (0.53) DUTP2RY2P2RY6P2RY4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12145951-B2 Inorganic-organic hybrid compounds including organic platinum-containing anions, for use in medicine KARLSRUHER INSTITUT FUR TECHNOLOGIE (DE) 2024-11-19 US claimed
US-20210292353-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-09-23 US claimed
EP-3829565-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE Karlsruher Institut für Technologie (DE) 2021-06-09 EP claimed
WO-2020025488-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE Karlsruher Institut für Technologie (DE) 2020-02-06 WO claimed
US-10086010-B2 Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells STC.UNM (US) 2018-10-02 US claimed
US-20180125875-A1 SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS THE REGENTS OF THE UNIVERSITY OF NEW MEXICO 2018-05-10 US claimed
US-20170112948-A1 Inorganic-organic hybrid compound Karlsruher Institut für Technologie (DE) 2017-04-27 US claimed
EP-3122756-A1 INORGANIC-ORGANIC HYBRID COMPOUND Karlsruher Institut für Technologie (DE) 2017-02-01 EP claimed
WO-2015144282-A1 INORGANIC-ORGANIC HYBRID COMPOUND Karlsruher Institut für Technologie (DE) 2015-10-01 WO claimed
WO-2015142867-A1 SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS STC.UNM (US) 2015-09-24 WO claimed
WO-2026090505-A1 FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2026-04-30 WO disclosed
CN-121673349-A Fluorodeoxyuridine monophosphate prodrug and application thereof in preparation of medicines for treating liver cancer 北京深蓝泰医药科技有限公司 2026-03-17 CN disclosed
CN-121673349-A Fluorodeoxyuridine monophosphate prodrug and application thereof in preparation of medicines for treating liver cancer 北京深蓝泰医药科技有限公司 2026-03-17 CN disclosed
EP-4680235-A1 COMPOSITIONS COMPRISING MELATONIN, 5-FLUOROURACIL AND DIMETHYL SULFOXIDE FOR USE IN THE TREATMENT OF ACTINIC KERATOSIS RepoCeuticals A/S (DK) 2026-01-21 EP disclosed
WO-2025151105-A1 5-FLUOROURACIL AND GENTISIC ACID LOADED NANOPARTICLE COATED WITH BIOTIN YILDIZ TEKNİK ÜNİVERSİTESİ DÖNER SERMAYE İŞLETME MÜD (TR) 2025-07-17 WO disclosed
EP-0594667-A1 TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES PRO-NEURON, INC. (US) 1994-05-04 EP disclosed
EP-0561303-A2 Conjugates of phenylalanine-glycine with antitumor substances KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 1993-09-22 EP disclosed
WO-1993002703-A1 PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS IGEN, INC. (US) 1993-02-18 WO disclosed
WO-1993001202-A1 TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES PRO-NEURON, INC. (US) 1993-01-21 WO disclosed
US-4755388-A Antiproliferative agent in liposome of cholesterol and phosphatidylglycerol THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1988-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170112948-A1 Inorganic-organic hybrid compound SLCO4C1, SLCO2A1, SLCO1A2 DUT 2168/4885P2RY2 1037/4885P2RY6 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.